Phytopharm: Commencement of Clinical Study of Cogane in Patients with Parkinson's disease
http://www.pharmalive.com/News/index...&categoryid=21
GODMANCHESTER, Cambridgeshire, England, 20 April 2009, Phytopharm plc today announces the commencement of a safety, tolerability and pharmacokinetic (PK) study of its orally active neurotrophic factor inducer PYM50028 (Cogane•), which will involve both healthy volunteers and patients with Parkinson’s disease (PD). This follows approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to commence recruitment for the UK study.